title: Indications to teriparatide treatment in patients with osteoporosis.
abstract: To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.
authors: Service of Bone Diseases,Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland. rene.rizzoli@unige.ch
authors: R
authors: R
authors: Rizzoli
authors: M
authors: M
authors: Kraenzlin
authors: M A
authors: MA
authors: Krieg
authors: H U
authors: HU
authors: Mellinghoff
authors: O
authors: O
authors: Lamy
authors: K
authors: K
authors: Lippuner
mesh_terms: D000368:Aged; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D019379:Teriparatide / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide